Absence of β-catenin mutations in mouse hepatoblastomas induced by N,N-dimethylformamide

Journal of Toxicologic Pathology

Volumn 17, Issue 4, 2004, Pages 261-265

  Kakuni, Masakazu ^a   Senoh, Hideki ^b   Morimura, Keiichirou ^a   Wanibuchi, Hideki ^a   Takaba, Katsumi ^a   Nagano, Kasuke ^b   Fukushima, Shoji ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Japan Bioassay Research Center   (Japan)

Author keywords

catenin; Dimethylformamide; DMF; Hepatoblastoma

Indexed keywords

EID: 23044456937     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.17.261     Document Type: Article

References (42)

1. Senoh H, Aiso S, Arito H, Nishizawa T, Nagano K, Yamamoto S, and Matsushima T. Carcinogenicity and chronic toxicity after inhalation exposure of rats and mice to N,N-dimethylformamide. J Occup Health 2004; 46: 429-439.
2. Blaker H, Hofmann WJ, Rieker RJ, Penzel R, Graf M, and Otto HF. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer 1999; 25: 399-402.
3. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, and Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59: 269-273.
4. Jeng YM, Wu MZ, Mao TL, Chang MH, and Hsu HC. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000; 152: 45-51.
5. Wei Y, Fabre M, Branchereau S, Gauthier F, Perilongo G, and Buendia MA. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 2000; 19: 498-504.
6. Park WS, Oh RR, Park JY, Kim PJ, Shin MS, Lee JH, Kim HS, Lee SH, Kim SY, Park YG, An WG, Jang JJ, Yoo NJ, and Lee JY. Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001; 193: 483-490.
7. Udatsu Y, Kusafuka T, Kuroda S, Miao J, and Okada A. High frequency of beta-catenin mutations in hepatoblastoma. Pediatr Surg Int 2001; 17: 508-512.
8. Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, and Devereux TR. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res 2000; 60: 2864-2868.
9. Cadigan KM and Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-3305.
10. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, and Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3 beta-dependent phosphorylation of beta-catenin. EMBO J 1998; 17: 1371-1384.
11. Aberle H, Bauer A, Stappert J, Kispert A, and Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
12. Munemitsu S, Albert I, Souza B, Rubinfeld B, and Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046-3050.
13. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, and Polakis P. Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. [see comment]. Science 1996; 272: 1023-1026.
14. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, and Polakis P. Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr Biol 1998; 8: 573-581.
15. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, and Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. [see comment]. Science 1997; 275: 1790-1792.
16. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, and Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
17. Kikuchi A. Regulation of beta-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000; 268: 243-248.
18. Eberling CL. In: Kirk-Othmer Encyclopedia of Chemical Technology, 3rd ed, HF Mark, DF Othmer, CG Overberger, and GT Seaborg (eds), New York: John Wiley and Sons, 263-268, 1980.
19. Marsella JA, Kroschwitz JI, and Howe-Grant M. Dimethylformamide. In: Kirk-Othmer Encyclopedia of Chemical Technology. New York: John Wiley and Sons, 1994.
20. Kimmerle G and Eben A. Metabolism studies of N,N-dimethylformamide. II. Studies in persons. Int Arch Arbeitsmed 1975; 34: 127-136.
21. Kimmerle G and Eben A. Metabolism studies of N,N-dimethylformamide. I. Studies in rats and dogs. Int Arch Arbeitsmed 1975; 34: 109-126.
22. Scailteur V and Lauwerys RR. Dimethylformamide (DMF) hepatotoxicity. Toxicology 1987; 43: 231-238.
23. Van den Bulcke M, Rosseel MT, Wijnants P, Buylaert W, and Belpaire FM. Metabolism and hepatotoxicity of N,N-dimethylformamide, N-hydroxymethyl-N- methylformamide, and N-methylformamide in the rat. Arch Toxicol 1994; 68: 291-295.
24. Chieli E, Saviozzi M, Menicagli S, Branca T, and Gervasi PG. Hepatotoxicity and P-4502E1-dependent metabolic oxidation of N,N-dimethylformamide in rats and mice. Arch Toxicol 1995; 69: 165-170.
25. Lundberg I, Lundberg S, and Kronevi T. Some observations on dimethylformamide hepatotoxicity. Toxicology 1981; 22: 1-7.
26. Ducatman AM, Conwill DE, and Crawl J. Germ cell tumors of the testicle among aircraft repairmen. J Urol 1986; 136: 834-836.
27. Levin SM, Baker DB, Landrigan PJ, Monaghan SV, Frumin E, Braithwaite M, and Towne W. Testicular cancer in leather tanners exposed to dimethylformamide. Lancet 1987; 2: 1153.
28. World Health Organization, International Agency for Research on Cancer. Dimethylformamide. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Lyon: WHO, 1999.
29. Pienta RJ, Poiley JA, and Lebherz WB. 3rd Morphological transformation of early passage golden Syrian hamster embryo cells derived from cryopreserved primary cultures as a reliable in vitro bioassay for identifying diverse carcinogens. Int J Cancer 1977; 19: 642-655.
30. Purchase IF, Longstaff E, Ashby J, Styles JA, Anderson D, Lefevre PA, and Westwood FR. Evaluation of six short term tests for detecting organic chemical carcinogens and recommendations for their use. Nature 1976; 264: 624-627.
31. Styles JA. Mammalian cell transformation in vitro: six tests for carcinogenicity. Br J Cancer 1978; 37: 931-936.
32. Williams GM. Detection of chemical carcinogens by unscheduled DNA synthesis in rat liver primary cell cultures. Cancer Res 1977; 37: 1845-1851.
33. Yamamoto S, Masui T, Murai T, Mori S, Oohara T, Makino S, Fukushima S, and Tatematsu M. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 1995; 16: 2363-2368.
34. Nollet F, Berx G, Molemans F, and van Roy F. Genomic organization of the human beta-catenin gene (CTNNB1). Genomics 1996; 32: 413-424.
35. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C, Kahn A, and Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95: 8847-8851.
36. Takahashi-Fujii A, Ishino Y, Kato I, and Fukumaki Y. Rapid and practical detection of beta-globin mutations causing beta-thalassemia by fluorescence-based PCR-single-stranded conformation polymorphism analysis. Mol Cell Probes 1994; 8: 385-393.
37. Kaneko M, Morimura K, Nishikawa T, Wanibuchi H, Takada N, Osugi H, Kinoshita H, and Fukushima S. Different genetic alterations in rat forestomach tumors induced by genotoxic and non-genotoxic carcinogens. Carcinogenesis 2002; 23: 1729-1735.
38. Bachmann M, Blaser P, Luthy J, and Schlatter C. Toxicity and mutagenicity of anthraquinones from Aspergillus chevalieri. J Environ Pathol Toxicol Oncol 1992; 11: 49-52.
39. Shane BS, deBoer JG, Glickman BW, and Cunningham ML. Oxazepam is mutagenic in vivo in Big Blue transgenic mice. Carcinogenesis 1999; 20: 1315-1321.
40. Chakrabarty S, McRae LJ, Levine AE, and Brattain MG. Restoration of normal growth control and membrane antigen composition in malignant cells by N,N-dimethylformamide. Cancer Res 1984; 44: 2181-2185.
41. Twiner MJ, Hirst M, Valenciano A, Zacharewski TR, and Dixon SJ. N,N-Dimethylformamide modulates acid extrusion from murine hepatoma cells. Toxicol Appl Pharmacol 1998; 153: 143-151.
42. Strazzabosco M and Boyer JL. Regulation of intracellular pH in the hepatocyte: mechanisms and physiological implications. J Hepatol 1996; 24: 631-644.